Abstract
Gyki 14,451, a peptide antagonist of thrombin, was tested on an in vivo model of venous thrombosis in the rat. At the 4 and 6 mg/kg i.v. doses, the compound caused a reduction of over 80% in the incidence of thrombus formation, also markedly reducing thrombus weight. Oral administration of Gyki 14,451 (50 and 50+50 mg/kg) did not induce a significant reduction either of thrombosis incidence or of thrombus weight.
Original language | English |
---|---|
Pages (from-to) | 549-553 |
Number of pages | 5 |
Journal | Thrombosis Research |
Volume | 23 |
Issue number | 6 |
DOIs | |
Publication status | Published - Sep 15 1981 |
Keywords
- Experimental venous thrombosis
- Thrombin inhibitors
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Hematology